2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society

Miki Fujimura,1 Teiji Tominaga,2 Satoshi Kuroda,3 Jun C. Takahashi,4 Hidenori Endo,5 Kuniaki Ogasawara,6 Susumu Miyamoto,7 Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) of the Ministry of Health, Labor Welfare, Japan, and the Guideline Committee 2021 of the Japan Stroke Society

1Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
2Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
3Department of Neurosurgery, University of Toyama School of Medicine, Toyama, Toyama, Japan
4Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
5Department of Neurosurgery, Kohnan Hospital, Sendai, Miyagi, Japan
6Department of Neurosurgery, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
7Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

Introduction

The angiographic characteristics of moyamoya disease (MMD) were first reported in 1957 as hypogenesis of bilateral internal carotid arteries (ICAs).1 Then, the concept of MMD was established as an independent disease entity in the 1960s.2-4 MMD is characterized by chronic progressive stenosis of the terminal portion of the bilateral ICAs, which leads to the formation of an abnormal vascular network, functioning as a collateral pathway at the base of the brain. The appearance of this vascular network on cerebral angiography was similar to a “puff of smoke,” which was described as “moyamoya” in Japanese.5 As the steno-occlusive changes of the bilateral ICAs progress, the moyamoya vessels eventually regress, and the entire cerebral hemisphere is perfused by the external carotid artery and the vertebrobasilar artery systems.6-7 MMD was designated as an intractable disease in Japan, which was initiated by the Intractable Disease Health Care Act to secure a budget for maintaining medical expense subsidy for patients with intractable diseases and to promote research on clarifying the pathogenesis. Presently, the diagnostic criteria for MMD are defined by the research committee approved by the Ministry of Health, Labor and Welfare of the Japanese government8 and then approved by the Japan Neurosurgical Society, the Japan Stroke Society, and the Japanese Society on Surgery for Cerebral Stroke. In this article, we report new guidelines for the management of MMD on the basis of 2021 guidelines from the Japan Stroke Society.9

[1] Surgical Treatment

Recommendations

i. Surgical revascularization is reasonable for MMD manifesting as cerebral ischemic symptoms (Appendix 1, Recommendation Grade B, Level of Evidence: low).

ii. Appropriate blood pressure control may be reasonable for patients with postoperative cerebral hyperperfusion syndrome while considering the concomitant cerebral ischemia (Recommendation Grade C, Level of Evidence: low).

Comments

i. Indication of surgery

Surgical revascularization for MMD patients with cerebral ischemic attacks has been reported to reduce the frequency of transient ischemic attacks (TIAs) and the risk of
Appendix 1  Classification of evidence levels and recommendation grades

| Evidence level | Definition                                                                 |
|----------------|----------------------------------------------------------------------------|
| High           | Consistent evidence from randomized controlled trials or exceptionally strong evidence from observational studies, which cannot be overturned by future studies. |
| Middle         | Evidence from randomized controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies, which can be overturned by future studies. |
| Low            | Evidence from observational studies, systematically nonorganized clinical studies, or randomized controlled trials with serious flaws. |

| Recommendation grade | Definition          | Comments                        |
|----------------------|---------------------|---------------------------------|
| A                    | Strong recommendation | Recommended Should perform      |
| B                    | Middle recommendation | Reasonable                      |
| C                    | Weak recommendation  | May/might be reasonable Undetermined effectiveness |
| D                    | Non-beneficial      | Not recommended Ineffective     |
| E                    | Harmful             | Recommended not to perform Should not perform |

cerebral infarction and to improve the postoperative activities of daily living (ADLs) and long-term prognosis of neurocognitive function.\(^{10-19}\) Improvement of cerebral hemodynamics and metabolism has been reported after revascularization surgery in patients with hemodynamic impairment on single-photon emission tomography (SPECT) or positron emission tomography (PET).\(^{10,17,20}\)

### ii. Surgical procedures

Revascularization procedures for MMD include direct revascularization, indirect revascularization, or a combination of these two types of surgery. Superficial temporal artery-middle cerebral artery anastomosis represents direct revascularization surgery. Indirect revascularization surgery includes encephalo-arterio-synangiosis, encephalo-duro-synangiosis, encephalo-myo-synangiosis, multiple burr hole surgery, or a combination of these procedures. Both direct and indirect revascularization or a direct/indirect combined revascularization surgery have been reported to improve cerebral hemodynamics, ameliorating the severity and frequency of TIAs, reducing the risk of cerebral infarction, and improving the postoperative ADL and long-term prognosis of neurocognitive function.\(^{10-21}\) For adult patients, the indirect procedure alone is not sufficient and a direct procedure or combined procedure is necessary.\(^{18,19,21-26}\) Moreover, a combined procedure supplies a wider territory of the ischemic brain than the direct procedure alone, resulting in better surgical outcomes for adult MMD patients.\(^{25}\) In pediatric patients, surgical revascularization, regardless of direct or indirect revascularization, has been reported to improve the clinical outcomes.\(^{17,26}\) Endovascular treatment for the steno-occlusive lesions of MMD is not recommended.\(^{29}\)

### iii. Perioperative management

Sufficient blood pressure control and fluid replacement, maintenance of normocapnia, and as-needed antiplatelet therapy are necessary for the perioperative management to avoid ischemic complications not only on the surgical side but also on the nonsurgical side.\(^{20}\) Transient neurological deterioration due to cerebral hyperperfusion syndrome or relevant delayed intracranial hemorrhage is of concern after revascularization surgery for MMD, especially in adult patients.\(^{31,32}\) Hence, it is recommended to assess cerebral hemodynamics in the early postoperative period to differentiate postoperative ischemia from hyperperfusion. Strict blood pressure control is effective for symptomatic hyperperfusion syndrome. Ischemic complications in a remote area or adjacent area of hyperperfusion (watershed shift phenomenon) should be watched for during strict blood pressure control.\(^{31,36}\) The perioperative administration of minocycline hydrochloride or edaravone may prevent symptomatic hyperperfusion.\(^{37,38}\)

### iv. Postoperative evaluation

The assessment of cerebral hemodynamics and metabo-
lism using PET or SPECT is useful for evaluating the effects of revascularization surgery. Cerebral angiography and magnetic resonance angiography (MRA) are useful for evaluating bypass development.

[2] Medical Treatment

Recommendations

i. Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) may be considered under careful evaluation of the risk of hemorrhagic complication in the hyperacute phase of cerebral ischemia in MMD (Recommendation Grade: C, Level of Evidence: low).

ii. Oral administration of antiplatelet agents may be considered as a medical treatment for ischemic MMD (Recommendation Grade: C, Level of Evidence: low).

iii. Reduction of systolic blood pressure may be reasonable in the acute stage of hemorrhagic MMD, as described for spontaneous intracerebral hemorrhage, considering the development of cerebral ischemia (Recommendation Grade: C, Level of Evidence: low).

Comments

The medical treatment of MMD is roughly classified into treatment for the acute phase of stroke, treatment for preventing recurrence in the chronic phase of stroke, and treatment of asymptomatic MMD.

1. Acute stage

i. Ischemic MMD

The intravenous administration of recombinant tissue-type plasminogen activator (rt-PA) therapy should be carefully considered in the hyperacute phase of ischemic onset MMD based on the “Guidelines of Proper Treatment with Intravenous Thrombolysis (rt-PA), the 3rd version (2019)”. In the acute phase of cerebral infarction in adults, edaravone or antiplatelet therapies are considered on the basis of the treatment of atherothrombotic cerebral infarction. For patients with large infarcts causing cerebral edema and intracranial hypertension, the use of glycerol should be considered. Furthermore, supportive treatment, such as antipyretics for fever, anticonvulsants for convulsions, control of blood sugar, oxygen supplementation for maintenance of arterial oxygen saturation, and prophylactic administration of antiulcer agents, is important. Maintenance of normocapnia should be indicated when mechanical ventilatory support is necessary. Regarding blood pressure control, as in the treatment of other cerebral infarctions, the blood pressure should not be reduced during the acute phase.

There is little evidence supporting a treatment strategy for ischemic MMD in children. Antiplatelet therapy with aspirin is generally used in the United States. If the patients exhibit aspirin resistance, low-molecular heparin can be used. Blood transfusion should be considered for patients with MMD associated with sickle cell disease because medical therapy is not effective for these patients. It should be noted that aspirin has a potential risk of Reye’s syndrome.

ii. Hemorrhagic MMD

In patients with hemorrhagic MMD, antihypertensive therapy can be considered on the basis of the treatment of hypertensive intracranial hemorrhage. Cerebral ischemic attack due to hypotension is of concern during antihypertensive therapy, although there is no evidence. The discontinuation of antiplatelet or anticoagulant therapies and the use of vitamin K, blood products, or antagonists should be considered.

2. Prevention of recurrence in the chronic stage

The surgical indications for the prevention of recurrent stroke should be primarily considered in patients with ischemic MMD. Medically, oral administration of antiplatelet drugs is the treatment of choice, but long-term administration has a potential risk of hemorrhagic transformation. Regular follow-up by T2*-weighted imaging for the detection of microbleeds may be effective to predict future hemorrhage. When aspirin is not effective to prevent an ischemic attack, clopidogrel or cilostazol can be considered. The safety of clopidogrel for pediatric patients has been validated. Long-term use of multiple antiplatelet agents is considered to have a high risk of hemorrhagic complications, especially in patients with brain atrophy or marked development of fragile moyamoya vessels.

General risk factors for stroke should be managed according to general practice. In terms of lifestyle guidance, hyperventilation often induces symptoms of ischemic attacks; therefore, pediatric patients should avoid hot meals (noodles, soup, etc.); strenuous exercise; playing wind instruments, such as a flute; and blowing balloons. In infants, it is important to avoid crying and dehydration due to vomiting and diarrhea.

3. Medical management of asymptomatic MMD

Asymptomatic MMD patients also have a risk of cerebrovascular events during follow-up. Management of risk factors and lifestyle guidance should be implemented according to the prevention of stroke recurrence in symptomatic MMD. The use of antiplatelet agents requires caution in adult patients while considering the potential risk for a hemorrhagic event in adult MMD.

4. Management in the perinatal period

Pregnancy and parturition are acceptable in female patients with MMD. Close cooperation with obstetricians and pediatricians is reasonable in the management of MMD patients in the perinatal period because we might not rule out the possibility of the increased risk of stroke.
during pregnancy, delivery, and postpartum period.

**3 Management of Hemorrhagic MMD**

**Recommendations**

Revascularization surgery is reasonable for hemorrhagic MMD, especially posterior hemorrhage, to prevent recurrent hemorrhage (Recommendation Grade: B, Level of Evidence: middle).

**Comments**

Intracranial hemorrhage is the most detrimental factor for the clinical prognosis of MMD. In the acute stage after intracranial hemorrhage, appropriate control of blood pressure and intracranial pressure by prompt medication and/or intraventricular drainage might be reasonable while considering the potential risk for concomitant cerebral ischemia in MMD. Disruption of the dilated collateral vessels (moyamoya vessels) due to hemodynamic stress or rupture of the peripheral aneurysms formed on the collateral vessels are possible sources of bleeding. Revascularization surgery is considered effective to reduce recurrent hemorrhage, considering that the postoperative angiography demonstrated regression of these collateral vessels or peripheral aneurysms after revascularization surgery. Furthermore, revascularization surgery is effective for patients with hemorrhagic MMD manifesting ischemic symptoms.

In Japan, a prospective randomized trial of extracranial-intracranial bypass surgery, Japan Adult Moyamoya (JAM) Trial, was conducted to investigate the efficacy of bypass surgery to prevent recurrent hemorrhage. In this trial, patients with hemorrhagic MMD were randomly assigned to two of the following groups: bilateral direct bypass surgery group and medical treatment alone group. The incidence of primary endpoints (all medical adverse events including rebleeding attacks) over 5 years was significantly lower in the surgical treatment group. Although the results were borderline significant, the efficacy of direct revascularization surgery to prevent recurrent bleeding was confirmed.

In the JAM Trial, the site of hemorrhage was classified as either anterior or posterior before assignment, and the clinical outcome and effects of surgery were compared between the two groups. Consequently, the annual rebleeding rate in the nonsurgical group was as high as 17.1% in the posterior hemorrhage group. Moreover, the preventive effects of surgery on rebleeding were significantly higher in the posterior hemorrhage group. Subgroup analysis demonstrated posterior cerebral artery stenosis and choroidal anastomosis to be relevant factors for posterior hemorrhage. The risk of hemorrhage was higher in the hemisphere with advanced choroidal anastomosis, which was a key angiographical prognostic factor. Furthermore, hemodynamic failure is an independent risk factor for subsequent hemorrhage in hemorrhagic MMD. Thus, along with the development of choroidal anastomosis, hemodynamic failure is an additional important factor to determine surgical indications.

**Conflicts of Interest Disclosure**

All authors have no conflicts of interest to declare. All authors who are members of The Japan Neurosurgical Society (JNS) have completed the Self-reported COI Disclosure Statement forms available at the website for JNS members.

**References**

1) Takeuchi K, Shimizu K: Hypogenesis of bilateral internal carotid arteries. No To Shinkei 9: 37-43, 1957
2) Kudo T: Occlusion of the internal carotid artery and the type of recovery of cerebral blood circulation. Rinsho Shinkeigaku 1: 199-200, 1960
3) Nishimoto A, Takeuchi S: Abnormal cerebrovascular network related to the internal carotid arteries. J Neurosurg 29: 255-260, 1968
4) Kudo T: Spontaneous occlusion of the circle of Willis. A disease apparently confined to Japanese. Neurology 18: 485-496, 1968
5) Suzuki J, Takaku A: Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20: 288-299, 1969
6) Suzuki J, Takaku A, Asahi M, Kowada M: [Study of diseases presenting fibrilla-like vessels at the base of brain (frequently found in the Japanese)]. No To Shinkei 17: 767-776, 1965
7) Suzuki J, Kodama N: Cerebrovascular “Moyamoya” disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus. Angiology 22: 223-236, 1971
8) Research on intractable diseases of the Ministry of Health LaW, Japan: Recommendations for the Management of Moyamoya Disease. A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease). Surgery for Cerebral Stroke 46: 1-24, 2018
9) Fujimura M: Management of Moyamoya disease, in Miyamoto S, the Guideline Committee 2021 of the Japan Stroke Society (eds): Japanese Guidelines for the Management of Sroke 2021. Tokyo, Kyowa-Kikaku, 2021, pp 213-217
10) Morimoto M, Iwama T, Hashimoto N, Kojima A, Hayashida K: Efficacy of direct revascularization in adult Moyamoya disease: haemodynamic evaluation by positron emission tomography. Acta Neurochir (Wien) 141: 377-384, 1999
11) Miyamoto S, Nagata I, Karasawa J, et al.: Long-term prognosis after direct bypass in Moyamoya disease. Surg Cereb Stroke 28: 111-114, 2000
12) Choi JU, Kim DS, Kim EY, Lee KC: Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups. Clin Neurol Neurosurg 99(Suppl 2): S11-S18, 1997
13) Scott RM, Smith JL, Robertson BL, Madsen JR, Soriano SG, Rockoff MA: Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100: 142-149, 2004
14) Matsushima Y, Aoyag M, Nariai T, et al.: Long-term prognosis of intelligence in childhood Moyamoya patients evaluated by Wechsler tests: I. Determination of standard changes in intelligence of
non-operated patients. Nervous System in Children 21: 224-231, 1996

15) Kawaguchi T, Fujita S, Hosoda K, et al.: Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 84: 468-476, 1996

16) Houkin K, Kuroda S, Nakayama N: Cerebral revascularization for moyamoya disease in children. Neurol Clin N Am 12: 575-584, ix, 2001

17) Kuroda S, Houkin K, Kaniyama H, Abe H, Mitsumori K: Regional cerebral hemodynamics in childhood moyamoya disease. Childs Nerv Syst 11: 584-590, 1995

18) Guzman R, Lee M, Achrol A, et al.: Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg 111: 927-935, 2009

19) Kim SK, Cho BK, Phi JH, et al.: Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68: 92-101, 2010

20) Ikezaki K, Matsushima T, Kuwabara Y, Suzuki SO, Nomura T, Fukui M: Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a perioperative positron emission tomography study. J Neurosurg 81: 843-850, 1994

21) Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW: Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg 128: 793-799, 2018

22) Mizoi K, Kayama T, Yoshimoto T, Nagamine Y: Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients? Surg Neurol 45: 541-548; discussion 548-549, 1996

23) Czabanka M, Vajkoczy P, Schmiedek P, Horn P: Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population. Neurosurg Focus 26: E9, 2009

24) Lee SB, Kim DS, Huh PW, Yoo DS, Lee TG, Cho KS: Long-term follow-up results in 142 adult patients with moyamoya disease according to management modality. Acta Neurochir (Wien) 154: 1179-1187, 2012

25) Cho WS, Kim JE, Kim CH, et al.: Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 45: 3025-3031, 2014

26) Deng X, Gao F, Zhang D, et al.: Direct versus indirect bypasses for adult ischemic-type moyamoya disease: a propensity score-matched analysis. J Neurosurg 128: 1785-1791, 2018

27) Matsushima T, Inoue T, Suzuki SO, Fujii K, Fukui M, Hasuo K: Surgical treatment of moyamoya disease in pediatric patients--comparison between the results of indirect and direct revascularization procedures. Neurosurgery 31: 401-405, 1992

28) Ishikawa T, Houkin K, Kaniyama H, Abe H: Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke 28: 1170-1173, 1997

29) Khan N, Dodd R, Marks MP, Bell-Stephens T, Vavao J, Steinberg GK: Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in Moyamoya angiopathy. Cerebrovasc Dis 31: 147-153, 2011

30) Iwama T, Hashimoto N, Yonekawa Y: The relevance of hemodynamic factors to perioperative ischemic complications in childhood moyamoya disease. Neurosurgery 38: 1120-1125; discussion 1125-1126, 1996

31) Fujimura M, Kaneta T, Mugikura S, Shimizu H, Tominaga T: Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 67: 273-282, 2007

32) Fujimura M, Shimizu H, Inoue T, Mugikura S, Saito A, Tominaga T: Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[[123I]iodoamphetamine single-photon emission computed tomography. Neurosurgery 68: 957-964; discussion 964-955, 2011

33) Uchino H, Kuroda S, Hirata K, Shiga T, Houkin K, Tamaki N: Predictors and clinical features of postoperative hyperperfusion after surgical revascularization for moyamoya disease: a serial single photon emission CT/positron emission tomography study. Stroke 43: 2610-2616, 2012

34) Kaku Y, Iliara K, Nakajima N, et al.: Cerebral blood flow and metabolism of hyperperfusion after cerebral revascularization in patients with moyamoya disease. J Cereb Blood Flow Metab 32: 2066-2075, 2012

35) Tashiro R, Fujimura M, Kameyama M, et al.: Incidence and risk factors of the watershed shift phenomenon after superficial temporal artery-middle cerebral artery anastomosis for adult Moyamoya disease. Cerebrovasc Dis 47: 178-187, 2019

36) Fujimura M, Inoue T, Shimizu H, Saito A, Mugikura S, Tominaga T: Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease. Cerebrovasc Dis 33: 436-445, 2012

37) Fujimura M, Niizuma K, Inoue T, et al.: Minocycline prevents focal neurological deterioration due to cerebral hyperperfusion after extracranial-intracranial bypass for moyamoya disease. Neurosurgery 74: 163-170; discussion 170, 2014

38) Uchino H, Nakayama N, Kazumata K, Kuroda S, Houkin K: Edaravone reduces hyperperfusion-related neurological deficits in adult Moyamoya disease: Historical control study. Stroke 47: 1930-1932, 2016

39) Honda M, Kitagawa N, Tsutsumi K, Morikawa M, Nagata I, Kaminogo M: Magnetic resonance angiography evaluation of external carotid artery tributaries in moyamoya disease. Surg Neurol 64: 325-330, 2005

40) Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T: How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst 20: 734-741, 2004

41) Members of Committee for medical improvement and social insurance Japan Stroke Society: Guidelines for proper treatment with intravenous rt-PA therapy, 3rd edition. 2019

42) Smith EB, Scott RM: Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr 9: 353-360, 2012

43) Yamada S, Oki K, Itoh Y, et al.: Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on Moyamoya disease in Japan. J Stroke Cerebrovasc Dis 25: 340-349, 2016

44) Kikutake K, Takagi Y, Nozaki K, et al.: Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study. J Neurosurg 102: 470-475, 2005

45) Komatsu T, Rafay MF, Hune S, Allen A, MacGregor D, deVeber G: The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 37: 1120-1122, 2006

46) Kuroda S, Hashimoto N, Yoshimoto T, Iwaski Y: Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke 38: 1430-1435, 2007

47) Liu XJ, Zhang D, Wang S, et al.: Intracranial hemorrhage from moyamoya disease during pregnancy and puerperium. Int J Gy-
48) Fluss R, Ligas BA, Chan AW, et al.: Moyamoya-related stroke risk during pregnancy: an evidence-based reappraisal. World Neurosurg 129: e582-e585, 2019
49) Maragkos GA, Ascanio LC, Chida K, et al.: Moyamoya disease in pregnancy: a systematic review. Acta Neurochir (Wien) 160: 1263-1273; discussion 1273-1264, 2000
50) Han DH, Kwon OK, Byun BJ, et al.: A co-operative study: clinical characteristics of 334 Korean patients with moyamoya disease treated at neurosurgical institutes (1976-1994). The Korean Society for Cerebrovascular Disease. Acta Neurochir (Wien) 142: 1263-1273; discussion 1273-1264, 2000
51) Kuroda S, Houkin K, Kamiyama H, Abe H: Effects of surgical revascularization on peripheral artery aneurysms in moyamoya disease: report of three cases. Neurosurgery 49: 463-467; discussion 467-468, 2001
52) Houkin K, Kamiyama H, Abe H, Takahashi A, Kuroda S: Surgical therapy for adult moyamoya disease. Can surgical revascularization prevent the recurrence of intracerebral hemorrhage? Stroke 27: 1342-1346, 1996
53) Kawaguchi S, Okuno S, Sakaki T: Effect of direct arterial bypass on the prevention of future stroke in patients with the hemorrhagic variety of moyamoya disease. J Neurosurg 93: 397-401, 2000
54) Miyamoto S: Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset—the Japan Adult Moyamoya Trial Group. Neurol Med Chir (Tokyo) 44: 218-219, 2004
55) Miyamoto S, Yoshimoto T, Hashimoto N, et al.: Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45: 1415-1421, 2014
56) Takahashi JC, Funaki T, Houkin K, et al.: Significance of the hemorrhagic site for recurrent bleeding: prespecified analysis in the Japan adult Moyamoya trial. Stroke 47: 37-43, 2016
57) Funaki T, Takahashi JC, Houkin K, et al.: High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. J Neurosurg 130: 337-673, 2019
58) Funaki T, Takahashi JC, Houkin K, et al.: Angiographic features of hemorrhagic moyamoya disease with high recurrence risk: a supplementary analysis of the Japan Adult Moyamoya Trial. J Neurosurg 134: 940-945, 2020

Corresponding author: Miki Fujimura, MD, PhD
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
e-mail: fujimur@med.hokudai.ac.jp